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Introduction: The	major	 complication	 of	 protein	 replacement	 therapy	 for	 haemo-
philia	 A	 is	 the	 development	 of	 anti‐FVIII	 antibodies	 or	 inhibitors	 that	 occur	 in	
25%‐30%	of	persons	with	 severe	haemophilia	A.	Alternative	 therapeutics	 such	as	
bypassing	agents	or	immune	tolerance	induction	protocols	have	additional	challenges	
and	are	not	always	effective.
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1  | INTRODUC TION: HAEMOPHILIA AND 
THE DE VELOPMENT OF INHIBITORS TO 









The	 current	 treatment	 for	 haemophilia	 is	 protein	 replacement	
therapy	with	plasma‐derived	or	recombinant	factor	VIII	proteins	that	
are	given	on‐demand	in	response	to	bleeds	or	prophylactically	with	
the	 goal	 of	 preventing	bleeding	 episodes.3	While	 this	 therapy	has	
transformed	the	care	of	PWHA,	the	major	complication	of	replace-









Both	genetic	 and	environmental	 risk	 factors	have	been	asso-
ciated	with	inhibitor	development.5,6	Genetic	factors	may	include	
the	FVIII	mutation,	the	severity	of	the	haemophilia,	family	history	
of	 inhibitors,	 ethnicity	 and	 polymorphisms	 of	 immune	 response	
genes.	 Environmental	 factors	 may	 include	 the	 FVIII	 product	
(plasma‐derived	vs	recombinant),	 intensity	of	FVIII	exposure,	age	
at	the	start	of	treatment	and	events	such	as	infection,	inflammation	











with	 additional	 challenges	 including	 reduced	 efficacy	 in	 the	 treat-
ment	or	prevention	of	haemorrhage	compared	to	FVIII	products	in	
those	without	an	inhibitor	and	the	inability	to	accurately	predict	the	
bleeding	 response.13-15	 An	 alternative	 approach	 for	 treating	 these	
patients	is	to	attempt	to	induce	immune	tolerance	to	the	FVIII	pro-
tein	 through	 immune	 tolerance	 induction	 (ITI)	 protocols.16	 Several	
ITI	regimens	have	been	developed	that	use	a	range	of	FVIII	dosing	
regimens,	 occasionally	 accompanied	 by	 immunomodulation.17,18 
However,	 the	 studies	 have	 not	 yielded	 a	 consensus	 on	 a	 practice	
approach	for	ITI	in	part	due	to	the	number	of	factors	that	influence	
the	success	of	ITI.	In	addition,	the	economic	burden	of	this	treatment	
is	 significant	 since	 the	 annual	 cost	 in	 the	United	 States	 increases	
between	 $150	000	 and	 $200	000	 without	 inhibitors	 to	 almost	
$1	000	000	with	an	inhibitor.19
Novel	 non‐factor	 therapeutics	 to	 treat	 haemophilia	 in	 the	
presence	of	 inhibitors	are	on	the	horizon.20-22	Emicizumab,	a	hu-
manized	bispecific	monoclonal	antibody	that	mimics	the	function	
of	 FVIII,	 has	 recently	 been	 approved	 for	 use	 in	 PWHA	 with	 or	










2  | ORIGINS OF THE STATE OF THE 
SCIENCE WORKSHOP
Within	the	United	States,	it	is	estimated	that	there	are	at	least	1000	
individuals	with	 a	 factor	VIII	 inhibitor.27	 The	Centers	 for	Disease	
Control	and	Prevention	(CDC)’s	Division	of	Blood	Disorders	(DBD)	
have	 been	 committed	 to	 the	 goal	 of	 reducing	 the	 occurrence	 of	
inhibitors,	 the	 most	 significant	 and	 costly	 complication	 affecting	
persons	 with	 haemophilia	 today.	 Following	 a	 multi‐stakeholder	






develop	 the	 methodology	 required	 for	 centralized	 sensitive	 and	
specific	 inhibitor	 testing.28	A	 second	multi‐stakeholder	 summit	 in	
2017	included	an	objective	to	explore	the	need	for	a	national,	pri-
oritized	 inhibitor	 scientific	 agenda	 and	 the	 blueprint	 for	 its	 coor-









•	 Multifaceted	education	 and	 informational	 activities	must	 be	di-
rected	to	the	patient	community	well	in	advance	of	upcoming	tri-
als	and	are	required	to	stimulate	interest	and	participation.


















the	 Division	 of	 Blood	 Diseases	 and	 Resources	 of	 the	 National	
Heart	 Lung	 and	 Blood	 Institute	 (NHLBI)/National	 Institutes	 of	
Health	 (NIH),	developed	the	concept	for	The	NHLBI	State	of	 the	
Science	(SOS)	Workshop.	The	goal	of	the	workshop	was	to	solicit	
input	 from	 the	 haemophilia	 community	 as	 well	 as	 from	 experts	
from	 outside	 the	 field	 into	 the	 development	 of	 a	 coordinated	
US‐based	blueprint	 for	 future	basic,	 translational	 and	 clinical	 re-
search	 focused	on	FVIII	 immunogenicity	and	 factor	VIII	 inhibitor	
prevention/eradication.






ship	 of	 the	 Scientific	 Working	 Groups,	 to	 oversee	 the	 pre‐SOS	
Working	Group	deliberations	 and	 to	 develop	 the	 SOS	Workshop	
agenda.	Four	 scientific	priorities	were	 identified	across	 the	spec-
trum	of	basic,	translational	and	clinical	research,	and	the	working	
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expertise	 from	 outside	 the	 field	 (Tables	 S1‐S4).	 Expertise	 from	
broad	 scientific	 areas	was	 assembled	 to	 include	FVIII	 biochemis-
try,	 immunology,	 “omics,”	 gene	 therapy,	maternal	 and	 foetal	biol-
ogy,	epidemiology,	and	computational	biology.	The	working	groups	
also	brought	together	extensive	knowledge	in	clinical	trial	design,	
biostatistics,	 human	 subjects	 research,	 biobanking,	 data	 sharing	
and	ethics.	The	pharmaceutical	industry	was	represented	on	each	
working	 group.	 The	 haemophilia	 community	was	 represented	 by	
PWH,	patient	 advocacy	groups	 and	members	of	 the	haemophilia	
treatment	 centres	 (HTC).	 Financial	 conflicts	 of	 interest	were	 de-
clared	to	the	Working	Group	Chairs,	as	well	as	to	the	NHLBI,	and	
were	presented	at	the	SOS	Workshop.
Once	 the	 working	 groups	 were	 formed,	 their	 deliberations	
began	 in	 January	 2018	 and	 continued	 in	 the	 form	 of	 bi‐weekly	
discussions	 to	 determine	 the	 scientific	 priorities	 in	 each	 area.	
In	 addition,	 there	 was	 significant	 crosstalk	 among	 the	 working	
groups.	On	15	and	16	May	2018,	the	culmination	of	these	efforts	
was	presented	as	a	draft	of	research	priorities	and	implementation	
strategies	 from	 each	 working	 group	 at	 the	 NHLBI	 State	 of	 the	




the	 haemophilia	 community	 provided	 insights	 on	 topics	 related	
to	each	of	the	four	working	group	scientific	priorities.	These	top-
ics	 included	clinical	 trial	design	 in	 the	age	of	personalized	medi-
cine	 (Nicholas	 Schork,	 PhD,	 J.	 Craig	 Venter	 Institute,	 University	
of	California,	San	Diego),	 learning	health	systems	 for	assembling	
clinical	 research	 data	 (Charles	 Bailey,	 MD,	 PhD,	 The	 Children's	
Hospital	 of	 Philadelphia),	 the	 development	 of	 patient	 registries	
and	 cohorts	 in	 rare	 diseases	 (Jennifer	Mulle,	 PhD,	MHS,	 Emory	
University)	 and	 the	 use	 of	 the	 knowledge	 of	 immune	 pathways	
to	 reduce	protein	 immunogenicity	 (Elizabeth	Mellins,	MD,	Lucile	
Salter	Packard	Children's	Hospital,	Stanford	University).	The	2‐day	
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18%	were	scientists	from	the	federal	government;	20%	were	from	
the	 pharmaceutical	 industry;	 and	 8%	 represented	 patient	 advo-
cacy	groups.	A	videocast	of	the	proceedings	was	archived	at	the	
NHLBI	and	is	available	for	public	viewing.29,30
3.1 | Working Group 1: scientific priorities and 




orities	 for	 investigator‐initiated	 clinical	 trials	 to	 include	 the	 opti-
mal	 integration	of	non‐intravenous,	non‐factor	novel	 therapeutics	





3.2 | Working Group 2: scientific priorities and 
strategies for 21st‐century data and specimen 






comparative	 short	 and	medium‐term	outcomes	 from	 the	 incorpo-
ration,	 or	 not,	 of	 non‐intravenous,	 non‐factor	 novel	 therapeutics,	
including	 gene	 therapy,	 into	 the	 standard	 of	 care	 for	 FVIII	 inhibi-
tors	(Table	2).	The	goals	for	this	group	focused	on	overcoming	the	
challenges	 associated	 with	 developing	 and	 maintaining	 data	 and	
biospecimen	 repositories	and	 included	deliberations	about	 the	 in-
frastructure	requirements	for	creating	a	data	and	biospecimen	re-
pository	as	well	 as	 strategies	 for	 implementation	of	 a	platform	 to	
establish	this	cohort.32
3.3 | Working Group 3: scientific priorities and 
implementation strategies for acquiring an actionable 
understanding of FVIII immunogenicity and the 
immunology of both the host immune 
response and tolerance
Co‐chaired	 by	 Shannon	 Meeks,	 MD	 and	 Roland	 Herzog,	 PhD,	
Working	Group	 3	was	 charged	with	 developing	 the	 scientific	 pri-
orities	 for	 acquiring	 an	 actionable	 understanding	 of	 FVIII	 immu-





3.4 | Working Group 4: design of pregnancy/birth 
longitudinal cohorts that leverage omics, existing 
phenotypic data and in silico modelling to study FVIII 
immunogenicity, as well as inhibitor development and 
eradication
Working	Group	 4,	 led	 by	Deborah	Brown,	MD	 and	 Jill	 Johnsen,	
MD,	was	charged	with	designing	of	prospective	pregnancy/birth	





studies,	 based	 on	 translational	 scientific	 priorities,	 required	 to	






ers	 in	 the	 challenge	 to	 eradicate	 and	 prevent	 inhibitors:	 the	 pa-
tients,	 clinicians,	 researchers,	 federal	 government	 and	 industry.	
Through	the	commitments	of	the	Executive	Steering	Committee,	
the	Working	Group	Chairs	 and	 all	 the	members	 of	 the	Working	
Groups,	 the	many	hours	of	deliberations	 lead	 to	a	 focused	sum-
mary	 of	 scientific	 priorities	 and	 implementation	 strategies	 to	
methodically	tackle	the	challenges	of	understanding	the	immune	
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